Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy

Conditions

• CD55-Deficient Protein-Losing Enteropathy

Eligibility Criteria

Sex

ALL

Age

1 Year - N/A

Healthy Volunteers

Not accepted

Interventions

• Pozelimab — DRUG
  Subcutaneous (SC) administration

Study Details

The program is to provide access to an experimental drug called pozelimab and to document the long-term safety of pozelimab in patients with Protein-Losing Enteropathy (PLE). CD55-deficient PLE/CHAPLE disease is a rare inherited disease of the immune system. This can be a life-threatening condition that is usually found when patients are children.

Key Dates

Status verified

Oct 2025